MSD’s Gardasil sales slide further due to China constraints
MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.
Biopharmaceutical Industry
FDA layoffs and priority review programme’s lapse disrupt rare disease pipeline
J&J projects $400m tariff hit but raises sales outlook
Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit
Keros Therapeutics considers sale amid investor pressure
MHRA reconfirmed as WHO biologics partner amid US withdrawal
Pharma CEOs warn EC President of “risk of exodus” to US
EU president to meet pharma leaders as tariff threat looms
